DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health National Cancer Institute Bethesda, Maryland

AGENDA

155th Meeting of the NATIONAL CANCER ADVISORY BOARD September 7- 8, 2010

<u>Tuesday, September 7 - OPEN</u> Conference Room 10, C Wing, Building 31

4:00 p.m. - 4:15 p.m.

I. CALL TO ORDER, OPENING REMARKS AND CONSIDERATION OF JUNE 2010 MINUTES

Dr. Chabner

II. FUTURE BOARD MEETING DATES

Confirmed:

December 6-8, 2010	Monday, Tuesday, Wednesday
February 7-9, 2011	Monday, Tuesday, Wednesday
June 27-29, 2011	Monday, Tuesday, Wednesday
September 12-14, 2011	Monday, Tuesday, Wednesday
December 5-7, 2011	Monday, Tuesday, Wednesday
February 6-8, 2012	Monday, Tuesday, Wednesday
June 18-20, 2012	Wednesday, Thursday, Friday
September 4-6, 2012	Tuesday, Wednesday, Thursday
November 28-30, 2012	Wednesday, Thursday, Friday

4:15 p.m. - 5:15 p.m.

III. NCI DIRECTOR'S REPORT Dr. Varmus

5:15 p.m. - 5:35 p.m.

IV. PRESIDENT'S CANCER PANEL REPORT Dr. Leffall

5:35 p.m. - 5:55 p.m.

V. LEGISLATIVE UPDATE Ms. Erickson

5:55 p.m.

VI. ADJOURNMENT

Wednesday, September 8 - CLOSED Conference Room 10, C Wing, Building 31

8:30 a.m. - 10:00 a.m.

VII. CLOSED SESSION

This portion of the meeting is being closed to the public in accordance with the Provisions set forth in Sections 552b(c) (4), 552b(c) (6). Title 5 U.S. Code and 10(d) of The Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2).

- GRANTS REVIEW
- DISCUSSION OF PERSONNEL AND PROPRIETARY ISSUES

10:00 a.m.

VIII. ADJOURNMENT OF CLOSED SESSION

10:00 a.m. - 10:15 a.m.

COFFEE BREAK

<u>Wednesday, September 8 - OPEN</u> Conference Room 10, C Wing, Building 31

10:15 a.m. - 11:15 a.m.

IX. STATUS REPORT: THE CANCER GENOME ATLAS (TCGA) Dr. Guyer

Dr. Chin

11:15 a.m. - 12:15 p.m.

X. STATUS REPORT: cancer BIOMEDICAL INFORMATICS GRID (caBIG) ACCOMPLISHMENTS

Dr. Buetow

12:15 p.m. - 1:15 p.m.

WORKING LUNCH

• NEW NCI FACILITIES: SHADY GROVE, RIVERSIDE AND OTHER NEW FACILITIES

Mr. Paunil

1:15 p.m. - 2:15 p.m.

XI. DEVELOPING A REPORT CARD FOR CLINICAL TRIAL ACTIVATION TIMELINES: INITIAL IMPLEMENTATION OF THE OEWG REPORT RECOMMENDATIONS

Dr. Doroshow

2:15 p.m. - 2:30 p.m.

XII. ONGOING AND NEW BUSINESS

2:30 p.m.

XIII. ADJOURNMENT